Physician profile
Naresh Kumar
NPI 1235147158
$330.93
in general payments reported to CMS, 2019-2025
13 companies · $50.60 in 2025
The $50.60 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $41.55 · 2022: $38.18 · 2023: $42.10 · 2025: $50.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $58.10 | 2019-2023 | Imfinzi |
| Regeneron Healthcare Solutions, INC. | $43.53 | 2019-2020 | |
| Celgene Corporation | $39.44 | 2019-2020 | |
| Geron Corporation | $27.21 | 2025 | Rytelo |
| Portola Pharmaceuticals, LLC | $25.03 | 2019 | |
| Blueprint Medicines Corporation | $23.39 | 2025 | Ayvakit |
| Seagen INC. | $22.29 | 2022 | |
| Taiho Oncology, INC. | $17.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.12 | 2019 | |
| Incyte Corporation | $16.53 | 2023 | Jakafi |
| Merck Sharp & Dohme LLC | $15.37 | 2019 | |
| Amgen INC. | $13.81 | 2019 | |
| Eisai INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.